S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy

S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices. This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs ...

Avsnitt(1066)

Populärt inom Vetenskap

p3-dystopia
svd-nyhetsartiklar
dumma-manniskor
allt-du-velat-veta
kapitalet-en-podd-om-ekonomi
rss-ufo-bortom-rimligt-tvivel--2
det-morka-psyket
rss-broccolipodden-en-podcast-som-inte-handlar-om-broccoli
medicinvetarna
rss-vetenskapsradion
hacka-livet
bildningspodden
rss-vetenskapsradion-2
rss-i-hjarnan-pa-louise-epstein
rss-vetenskapspodden
vetenskapsradion
a-kursen
rss-spraket
sexet
paranormalt-med-caroline-giertz